Top Markets
#1 Trillions Trillions +4,371.22%
#2 Ozapay Ozapay +37.63%
#3 UnifAI Network UnifAI Network +26.77%
#4 Aria.AI Aria.AI +21.95%
#5 Zano Zano +17.34%
#6 Osaka Protocol Osaka Protocol +14.21%
#7 StakeStone StakeStone +13.94%
#8 Vestra DAO Vestra DAO +11.91%
#9 River Pts River Pts +10.84%
#10 pippin pippin +10.64%
Coin of the day
Trillions Trillions
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rangering i aksjer #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Aksjekurs
$0.28545656
Markedsverdi
$4.50M
Endring (1 dag)
5.97%
Endring (1 år)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategori

Healthcare
Inntekter for Acticor Biotech SAS (ALACT)
Inntekter i Jun 2024 TTM: $-12.93M
Ifølge Acticor Biotech SAS sine nyeste økonomiske rapporter er selskapets nåværende resultat $-12.93M. I 2022 hadde selskapet et resultat på $-19.33M, en nedgang sammenlignet med resultatet i 2021, som var $-16.54M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Acticor Biotech SAS fra 2010 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -158,354.90%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -36,019.43%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -40,564.29%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -16,637.04%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -12,587.97%
AU